LISA-TRACKER anti-Adalimumab
Product Description
LISA-TRACKER anti-Adalimumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of human anti-Adalimumab antibodies in human serum samples.
- Comprehensive menu in inflammatory diseases and oncology
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – protocols available on several open platform ELISA systems
-
- Assa A & al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn’s Disease Compared With Reactive Monitoring Gastroenterology . 2019 Oct;157(4):985-996.e2.
- Bartelds GM & al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011 Apr 13;305(14):1460-8.
- Gibson DJ & al. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2020 Mar;51(6):612-628.
- Labetoulle R & al. Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy. Ann Intern Med. 2018 Mar 6.
- Quistrebert J & al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Semin Arthritis Rheum. 2018 Oct 12. pii: S0049-0172(18)30176-8.
- Radstake TRDJ & al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739–1745.
- Product Code: LTI-003-48
- Number of Tests: 48
- Sample Type: Serum or plasma
- Sample Volume: 100 μL (following predilution)
- Assay Range: 10 – 160 ng/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| LISA-TRACKER Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Certolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Etanercept | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Golimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Rituximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Secukinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Tocilizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Ustekinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Vedolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD |